These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 8978923)
1. Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine. Vidor E; Xueref C; Blondeau C; Bajard A; Francon A; Goudeau A; Peyron F; Brasseur P; Zuckerman A Biologicals; 1996 Sep; 24(3):235-42. PubMed ID: 8978923 [TBL] [Abstract][Full Text] [Related]
2. Early appearance of neutralizing antibodies after vaccination with an inactivated hepatitis A vaccine. Flehmig B; Staedele H; Xueref C; Vidor E; Zuckerman J; Zuckerman A J Infect; 1997 Jul; 35(1):37-40. PubMed ID: 9279722 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children. Lee CY; Huang LM; Lee PI; Chiu HH; Dumas R; Milcamps B; Lin W Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):29-36. PubMed ID: 11023061 [TBL] [Abstract][Full Text] [Related]
4. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. Van Herck K; Beutels P; Van Damme P; Beutels M; Van den Dries J; Briantais P; Vidor E J Med Virol; 2000 Jan; 60(1):1-7. PubMed ID: 10568755 [TBL] [Abstract][Full Text] [Related]
5. A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine. Green MS; Cohen D; Lerman Y; Sjogren M; Binn LN; Zur S; Slepon R; Robin G; Hoke C; Bancroft W Isr J Med Sci; 1994; 30(5-6):485-8. PubMed ID: 8034508 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917 [TBL] [Abstract][Full Text] [Related]
7. [Comparison of immunology effects between live attenuated hepatitis A vaccine and inactivated hepatitis A vaccine]. Wang X; Meng Z; Li R Zhonghua Yi Xue Za Zhi; 2000 Jun; 80(6):422-4. PubMed ID: 11798797 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a new inactivated hepatitis A vaccine in Thai young adults. Vimolket T; Theamboonlers A; Dumas R; Milcamps B; Forrat R; Poovorawan Y Southeast Asian J Trop Med Public Health; 1998 Dec; 29(4):779-85. PubMed ID: 10772564 [TBL] [Abstract][Full Text] [Related]
9. [Reactivity and immunogenicity of Havrix 360 vaccine for hepatitis A]. Borcić B; Kovac S; Mihaljević I; Dobrovsak-Sourek V; Ljubicić M Lijec Vjesn; 1996; 118(7-8):162-4. PubMed ID: 8965633 [TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix. Connor BA; Phair J; Sack D; McEniry D; Hornick R; Banerjee D; Jensen E; Kuter B Clin Infect Dis; 2001 Feb; 32(3):396-401. PubMed ID: 11170947 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. Goilav C; Zuckerman J; Lafrenz M; Vidor E; Lauwers S; Ratheau C; Benichou G; Zuckerman A J Med Virol; 1995 Jul; 46(3):287-92. PubMed ID: 7561805 [TBL] [Abstract][Full Text] [Related]
12. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Kanra G; Yalçin SS; Ceyhan M; Yurdakök K Turk J Pediatr; 2000; 42(2):105-8. PubMed ID: 10936974 [TBL] [Abstract][Full Text] [Related]
13. [Evaluation of immunogenicity and safety in healthy adults of an inactivated anti-hepatitis A vaccine]. Gil A; González A; Dal-Ré ; Aguilar L; Malo C; del Rey J Med Clin (Barc); 1994 May; 102(20):769-71. PubMed ID: 8041214 [TBL] [Abstract][Full Text] [Related]
14. [Immune response to a single dose of a novel kind of hepatitis A vaccine following splenectomy]. Simmen HP; Robustelli L; Althaus B; Glück R; Trentz O; Vogt M Dtsch Med Wochenschr; 1996 Mar; 121(10):295-8. PubMed ID: 8681712 [TBL] [Abstract][Full Text] [Related]
15. Single dose-inactivated hepatitis A vaccination schedule for susceptible youngsters. Lee SD; Chan CY; Yu MI; Wang YJ; Lo KJ; Safary A Am J Gastroenterol; 1996 Jul; 91(7):1360-2. PubMed ID: 8677995 [TBL] [Abstract][Full Text] [Related]
16. [Safety and immunogenicity of a new inactivated hepatitis A vaccine]. Ren A; Ma J; Feng F Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Dec; 15(4):357-9. PubMed ID: 11986726 [TBL] [Abstract][Full Text] [Related]
17. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. Wiens BL; Bohidar NR; Pigeon JG; Egan J; Hurni W; Brown L; Kuter BJ; Nalin DR J Med Virol; 1996 Jul; 49(3):235-41. PubMed ID: 8818971 [TBL] [Abstract][Full Text] [Related]
18. Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine. Goubau P; Van Gerven V; Safary A; Delem A; Knops J; D'Hondt E; André FE; Desmyter J Vaccine; 1992; 10 Suppl 1():S114-8. PubMed ID: 1335638 [TBL] [Abstract][Full Text] [Related]
19. Acute hepatitis A in a traveler who had received preexposure inactivated hepatitis A virus vaccine. Kurup A; San LM; Yew WS Clin Infect Dis; 1999 Jun; 28(6):1324-5. PubMed ID: 10451178 [No Abstract] [Full Text] [Related]
20. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. Van Damme P; Thoelen S; Cramm M; De Groote K; Safary A; Meheus A J Med Virol; 1994 Dec; 44(4):446-51. PubMed ID: 7897379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]